EyeYon Medical announced today the completion of a $25 million in a Series C funding

EyeYon Medical announced today the completion of a $25 million in a Series C funding, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund, which invests in life science companies that develop drugs, cell therapies, medical devices, and smart healthcare technology. Other participants in the round include Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund. 
EyeYon Medical was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera MD, and Dr. Arie Marcovich, MD., and develops advanced technology to treat acute problems in the ophthalmic world. The latest round brings the total amount of capital raised by the company to $36 million.
The new capital will be used to expand the clinical trials of EyeYon Medical’s flagship product, the EndoArt®, the world’s first synthetic implant which enables doctors to treat chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue. With more than 13 million on the waiting list for corneal transplant, the EndoArt® was created in an effort to ease global shortages of corneal donations. Clinical trials, which are already underway in selected medical centers across Europe (IVRC in Heidelberg, Instituto de Microcirugia Ocular (IMO) in Barcelona, and AMC in Amsterdam) and in Israel (Soroka Medical Center, Rambam Health Care Campus, Tel Aviv Sourasky Medical Center and Barzilai Medical Center) have demonstrated the safety and efficacy of EyeYon Medical’s groundbreaking technology. 
Following the new investments, EyeYon Medical will expand its clinical trials with the aim to receive regulatory approval in the USA, China and Europe and leverage the company’s extensive professional network and the high demand for the product.
Nahum Ferera, Co-Founder and CEO of EyeYon Medical, said: “The overwhelming interest in joining our latest funding round reflects the confidence that investors have in our unique and disruptive technology and its tremendous ability to address the clinical challenges and the huge market opportunity in the growing corneal implants market. Together with our team of clinical and medical device experts, we have developed a novel solution which has already shown groundbreaking results and safety in human trials. The latest investments position EyeYon Medical as a global pioneer in the ophthalmology space and in corneal care.”
EyeYon Medical is a start-up company developing a variety of ophthalmic products for vision-threatening conditions. EyeYon Medical's flagship product is an Artificial Endothelial Layer - EndoArt®, a synthetic implant, attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction. A nonfunctioning endothelium results in corneal homeostasis loss due to excess fluid flowing into the cornea, resulting in severe vision loss. The minimally invasive EndoArt® is designed to replace dysfunctional endothelium to cure corneal Edema, offering a safer and simpler solution that will be available to anyone, anywhere. EyeYon Medical also developed the Hyper CL™, an FDA approved unique contact lens that acts as a premium therapeutic contact lens for a variety of corneal conditions which require eye drop treatment.